Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00211198
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : March 5, 2008
Tufts Medical Center
National Cancer Institute (NCI)
Ligand Pharmaceuticals
Information provided by:
Eisai Inc.

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : January 2005
  Study Completion Date : January 2006
Francine Foss, Madeleine Duvic, Larisa Geskin, Joseph Anderson, Pierluigi Porcu, Raymond J. Hohl, Maureen Cooper, Jasmine M. Zain, John Zic, Patrica Hibberd, and Mark Acosta Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status. Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 2712.